You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康寧傑瑞製藥-B(9966.HK)反彈逾6% 兩項新藥臨牀試驗獲批
格隆匯 02-15 11:10
格隆匯2月15日丨康寧傑瑞製藥-B(9966.HK)拉昇反彈6.3%,現報10.12港元,暫成交1357萬港元,總市值94.8億港元。公司近日從國家藥監局收到兩項新藥臨牀試驗批准,包括啟動集團自主研發的PD-L1/OX40雙特異性抗體KN052的Ia/Ib期臨牀試驗,及啟動集團自主研發的PD-L1/CTLA-4雙特異性抗體KN046的II期臨牀試驗。據悉,KN046已經在全球開展覆蓋十餘種腫瘤的近20項不同階段臨牀試驗。正在探索與其商業合作伙伴候選藥物聯合開展KN046臨牀試驗合作機會,從而實現更好的療效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account